Eton Pharmaceuticals (NASDAQ:ETON) Trading Down 4.6% – What’s Next?

Posted by Brian Himes on Aug 5th, 2026

Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Free Report) fell 4.6% during mid-day trading on Monday . The company traded as low as $43.49 and last traded at $44.2750. Approximately 185,599 shares traded hands during trading, a decline of 53% from the average daily volume of 392,865 shares. The stock had previously closed at $46.42.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Canaccord Genuity Group initiated coverage on Eton Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating and a $60.00 target price on the stock. Zacks Research lowered shares of Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. HC Wainwright raised their price objective on Eton Pharmaceuticals from $52.00 to $57.00 and gave the company a “buy” rating in a report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. Finally, Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Eton Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $52.50.

Check Out Our Latest Report on ETON

Eton Pharmaceuticals Stock Up 1.5%

The company has a market cap of $1.26 billion, a price-to-earnings ratio of -654.62 and a beta of 0.86. The firm has a 50-day moving average price of $36.52 and a 200 day moving average price of $26.98. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.21 and a quick ratio of 0.88.

Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. The business had revenue of $24.27 million during the quarter, compared to the consensus estimate of $22.31 million. Sell-side analysts predict that Eton Pharmaceuticals, Inc. will post 0.75 EPS for the current year.

Insider Activity at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, Director Jennifer Mckie Adams sold 50,000 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the completion of the sale, the director directly owned 50,000 shares in the company, valued at $1,624,000. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Krempa sold 42,797 shares of Eton Pharmaceuticals stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $33.39, for a total value of $1,428,991.83. Following the completion of the transaction, the insider owned 25,249 shares in the company, valued at approximately $843,064.11. The trade was a 62.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 150,000 shares of company stock valued at $4,853,921. Company insiders own 16.49% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Opaleye Management Inc. boosted its stake in shares of Eton Pharmaceuticals by 0.3% in the 2nd quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock valued at $40,755,000 after purchasing an additional 7,930 shares in the last quarter. EcoR1 Capital LLC increased its position in Eton Pharmaceuticals by 7.0% during the 1st quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock worth $53,603,000 after purchasing an additional 141,394 shares in the last quarter. Vanguard Group Inc. lifted its stake in Eton Pharmaceuticals by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock valued at $29,208,000 after purchasing an additional 31,942 shares during the last quarter. State Street Corp boosted its position in Eton Pharmaceuticals by 14.5% in the fourth quarter. State Street Corp now owns 501,925 shares of the company’s stock valued at $8,488,000 after buying an additional 63,480 shares in the last quarter. Finally, Millennium Management LLC grew its stake in shares of Eton Pharmaceuticals by 156.3% during the first quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock worth $4,620,000 after buying an additional 217,042 shares during the last quarter. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

(Get Free Report)

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.